What is a Blood-Enriching Injection?

Blood-enriching injection is actually vitamin B12 injection. If symptoms such as dizziness and fatigue occur, and the examination finds decreased hemoglobin and vitamin B12 in the serum, it is classified as benign anemia. Blood-enriching injection can be used for conditioning and treatment. During the injection, it is recommended to measure blood pressure daily, perform routine blood tests monthly, and adjust medication appropriately based on the test results.

Generally speaking, blood-enriching injection usually refers to vitamin B12 injection, which is mainly used for patients with megaloblastic anemia caused by vitamin B12 deficiency. Clinically, patients may experience symptoms of anemia such as general fatigue, dizziness, and palpitations, with decreased hemoglobin in routine blood tests, indicating macrocytic anemia. The level of vitamin B12 in the serum is significantly reduced. This type of anemia is considered benign. After supplementation with vitamin B12, hemoglobin levels can be completely restored to normal in most patients within 1-2 months.

1. Measure blood pressure three times a day (morning, noon, and evening). If blood pressure rises, please report to the doctor for adjustment of antihypertensive medication.

2. Check the condition of arteriovenous fistula daily. Feel for any tremors by hand, and use a stethoscope to listen for any vascular murmurs. If the fistula tremor weakens or disappears, please seek immediate medical attention.

3. Perform routine blood tests monthly to adjust medication dosages and maintain hemoglobin levels between 11-12g/dl.

4. Check serum iron, ferritin, and transferrin saturation every three months to determine the need for oral or intravenous iron supplementation.

5. Properly store the medication: keep it in a cool place (2-8°C) away from light, heat, cold, and vibration.

Note: Blood-enriching injection is not suitable or necessary for patients with already high hemoglobin levels, blood pressure higher than 170/100mmHg, allergies to certain erythropoietic agents, or patients with epilepsy.